A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP
Phase 2
40
about 4.7 years
70+
1 site in NY
What this study is about
This trial is testing whether adding mosunetuzumab to treatment can help older patients with DLBCL who have detectable ctDNA in their blood. The goal is to see if this approach leads to better disease control and outcomes for these patients, as well as assess the safety of this regimen.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Mosunetuzumab
- 2.Use ClonoSEQ
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
mosunetuzumab
Primary: ctDNA clearance rate after mosunetuzumab treatment
Secondary: Objective response rate and complete response rate of pola-R-mini-CHP